Zobrazeno 1 - 10
of 144
pro vyhledávání: '"Thomas Hatschek"'
Autor:
Thomas Fleischer, Mads Haugland Haugen, Jørgen Ankill, Laxmi Silwal‐Pandit, Anne‐Lise Børresen‐Dale, Ingrid Hedenfalk, Thomas Hatschek, Jörg Tost, Olav Engebraaten, Vessela N. Kristensen
Publikováno v:
Molecular Oncology, Vol 18, Iss 8, Pp 2042-2059 (2024)
Treatment with the anti‐angiogenic drug bevacizumab in addition to chemotherapy has shown efficacy for breast cancer in some clinical trials, but better biomarkers are needed to optimally select patients for treatment. Here, we present an omics app
Externí odkaz:
https://doaj.org/article/943a77752b1e4da48443c28cd3393e9f
Autor:
Kang Wang, Ioannis Zerdes, Henrik J. Johansson, Dhifaf Sarhan, Yizhe Sun, Dimitris C. Kanellis, Emmanouil G. Sifakis, Artur Mezheyeuski, Xingrong Liu, Niklas Loman, Ingrid Hedenfalk, Jonas Bergh, Jiri Bartek, Thomas Hatschek, Janne Lehtiö, Alexios Matikas, Theodoros Foukakis
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-24 (2024)
Abstract Although metabolic reprogramming within tumor cells and tumor microenvironment (TME) is well described in breast cancer, little is known about how the interplay of immune state and cancer metabolism evolves during treatment. Here, we charact
Externí odkaz:
https://doaj.org/article/b1fcc99c167b4d128ce9d55c41851b89
Autor:
Anna Nordenskjöld, Helena Fohlin, Johan Rosell, Nils-Olof Bengtsson, Tommy Fornander, Thomas Hatschek, Henrik Lindman, Per Malmström, Lisa Rydén, Arne Wallgren, Olle Stål, Bo Nordenskjöld
Publikováno v:
Breast, Vol 71, Iss , Pp 63-68 (2023)
Background: Tamoxifen is an established treatment for breast cancer, but its long-term effects on survival and on secondary cancers are not fully evaluated. Material and methods: We studied 30 years outcome of 4124 postmenopausal patients who were ra
Externí odkaz:
https://doaj.org/article/487528a90ae34cc4bee6e74d37bc5e34
Autor:
Sibylle Loibl, Chiun-Sheng Huang, Max S. Mano, Eleftherios P. Mamounas, Charles E. Geyer, Michael Untch, Jean-Christophe Thery, Ingo Schwaner, Steven Limentani, Niklas Loman, Kristina Lübbe, Jenny C. Chang, Thomas Hatschek, David Tesarowski, Chunyan Song, Sanne Lysbet de Haas, Thomas Boulet, Chiara Lambertini, Norman Wolmark
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-6 (2022)
Abstract Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated
Externí odkaz:
https://doaj.org/article/c268c669d03547e1b3867ec85f83f413
Autor:
Oscar Briem, Eva Källberg, Siker Kimbung, Srinivas Veerla, Jenny Stenström, Thomas Hatschek, Catharina Hagerling, Ingrid Hedenfalk, Karin Leandersson
Publikováno v:
Cancers, Vol 15, Iss 4, p 1262 (2023)
The presence of CD169+ macrophages in the draining lymph nodes of cancer patients is, for unknown reasons, associated with a beneficial prognosis. We here investigated the prognostic impact of tumor-infiltrating CD169+ macrophages in primary tumors (
Externí odkaz:
https://doaj.org/article/6e8658af9bf44d5e833e45f05cccae28
Autor:
Mohammad A. Alzubi, Tia H. Turner, Amy L. Olex, Sahib S. Sohal, Nicholas P. Tobin, Susana G. Recio, Jonas Bergh, Thomas Hatschek, Joel S. Parker, Carol A. Sartorius, Charles M. Perou, Mikhail G. Dozmorov, J. Chuck Harrell
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-15 (2019)
Abstract Background The seed and soil hypothesis was proposed over a century ago to describe why cancer cells (seeds) grow in certain organs (soil). Since then, the genetic properties that define the cancer cells have been heavily investigated; howev
Externí odkaz:
https://doaj.org/article/4c6513371deb4dd18f222731bbba6ee5
Autor:
Bo Franzén, Andrey Alexeyenko, Masood Kamali‐Moghaddam, Thomas Hatschek, Lena Kanter, Torbjörn Ramqvist, Jonas Kierkegaard, Giuseppe Masucci, Gert Auer, Ulf Landegren, Rolf Lewensohn
Publikováno v:
Molecular Oncology, Vol 13, Iss 2, Pp 376-391 (2019)
There are increasing demands for informative cancer biomarkers, accessible via minimally invasive procedures, both for initial diagnostics and for follow‐up of personalized cancer therapy, including immunotherapy. Fine‐needle aspiration (FNA) bio
Externí odkaz:
https://doaj.org/article/7288d55d153b40039adf7d17f06c62a1
Autor:
Bo Franzén, Masood Kamali‐Moghaddam, Andrey Alexeyenko, Thomas Hatschek, Susanne Becker, Lotta Wik, Jonas Kierkegaard, Annika Eriksson, Naveen R. Muppani, Gert Auer, Ulf Landegren, Rolf Lewensohn
Publikováno v:
Molecular Oncology, Vol 12, Iss 9, Pp 1415-1428 (2018)
There are increasing demands for informative cancer biomarkers, accessible via minimally invasive procedures, both for initial diagnostics and to follow‐up personalized cancer therapy. Fine‐needle aspiration (FNA) biopsy provides ready access to
Externí odkaz:
https://doaj.org/article/801210110a314b449358aec16284a545
Autor:
Una Kjällquist, Rikard Erlandsson, Nicholas P. Tobin, Amjad Alkodsi, Ikram Ullah, Gustav Stålhammar, Eva Karlsson, Thomas Hatschek, Johan Hartman, Sten Linnarsson, Jonas Bergh
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-17 (2018)
Abstract Background Tumor heterogeneity in breast cancer tumors is today widely recognized. Most of the available knowledge in genetic variation however, relates to the primary tumor while metastatic lesions are much less studied. Many studies have r
Externí odkaz:
https://doaj.org/article/16b1daf21e6b406297d8329ccb94c5fd
Autor:
Ioannis Zerdes, Vaia Karafousia, Artur Mezheyeuski, Maria Stogiannitsi, Raoul Kuiper, Pablo Moreno Ruiz, George Rassidakis, Jonas Bergh, Thomas Hatschek, Theodoros Foukakis, Alexios Matikas
Publikováno v:
Cancers, Vol 13, Iss 18, p 4655 (2021)
We aimed to assess if the discrepant prognostic information between Programmed Death Ligand 1 (PD-L1) protein versus mRNA expression in early breast cancer (BC) could be attributed to heterogeneity in its expression. PD-L1 protein and mRNA expression
Externí odkaz:
https://doaj.org/article/ef6772e8b7224629a7c4efa27498c188